Predictive values of urinary bladder tumor markers survivin and soluble-Fas comparison with cystoscopy and bladder tumor antigen

Minerva Urologica e Nefrologica

Volumn 64, Issue 4, 2012, Pages 279-285

  Ganas, V ^a   Kalaitzis, C ^b   Sountoulides, P ^c   Giannakopoulos, S ^b   Touloupidis, S ^b  

^a Elpis Hospital   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c GENERAL HOSPITAL OF VERIA   (Greece)

Author keywords

Neoplasm proteins; Tumor markers, biological; Urinary bladder neoplasms

Indexed keywords

BLADDER TUMOR ANTIGEN; FAS ANTIGEN; SURVIVIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; URINALYSIS;

AGED; AGED, 80 AND OVER; ANTIGENS, CD95; ANTIGENS, NEOPLASM; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; CYSTOSCOPY; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SOLUBILITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84875327495     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96. (Pubitemid 351521864)
2. Malkowicz SB, van Poppel H, Mickisch G, Pansadoro V, Thüroff J, Soloway MS et al. Muscle-invasive urothelial carcinoma of the bladder. Urology 2007;69(1 Suppl):3-16. (Pubitemid 46186483)
3. Rubben H, Lutzeyer W, Fischer N, Deutz F, Lagrange W, Giani G. Natural history and treatment of low and high risk superficial bladder tumors. J Urol 1988;139:283-5.
4. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003;21:1315-30. (Pubitemid 38041357)
5. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP 3rd et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005;66:35-63. (Pubitemid 43049608)
6. Yossepowitch O, Herr HW, Donat SM. Use of urinary biomarkers for bladder cancer surveillance: patient perspectives. J Urol 2007;177:1277-82. (Pubitemid 46436000)
7. Depraetere V, Golstein P. Fas and other cell death signalling pathways. Semin Immunol 1997;9:93-107. (Pubitemid 27281472)
8. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995;16:39-43.
9. Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994;265:528-30. (Pubitemid 24264998)
10. Arase H, Arase N, Saito T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med 1995;181:1235-8.
11. Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 1995;154:2706-13.
12. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263:1759-62. (Pubitemid 24131584)
13. Papoff G, Cascino I, Eramo A, Starace G, Lynch DH, Ruberti G. An N-terminal domain shared by Fas/Apo1 (CD95) soluble variants prevents cell death in vitro. J Immunol 1996;156:4622-30. (Pubitemid 26174442)
14. Perabo FG, Mattes RH, Wirger A, Steiner G, Kamp S, Schmidt D et al. Soluble Fas and Fas-ligand in bladder cancer in vitro and in vivo. Urol Oncol 2001;6:163-9. (Pubitemid 32552017)
15. Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI et al. Soluble Fas-A promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer 2006;106:1701-7.
16. Lokeshwar VB, Soloway MS. Current bladder tumor tests: does their projected utility fulfill clinical necessity? J Urol 2001;165:1067-77. (Pubitemid 32210202)
17. Stein JP, Grossfeld GD, Ginsberg DA, Esrig D, Freeman JA, Figueroa AJ et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 1998;160:645-59. (Pubitemid 29479481)
18. O'Driscoll L, Linehan R, Clynes M. Survivin: role in normal cells and in pathological conditions. Curr Cancer Drug Targets 2003;3:131-52. (Pubitemid 36389551)
19. Ambrosini G, Adida C, Altieri DC. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21. (Pubitemid 27353455)
20. Monzó M, Rosell R, Felip E, Astudillo J, Sánchez JJ, Maestre J et al. A novel antiapoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999;17:2100-4. (Pubitemid 29318841)
21. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000;6:127-34. (Pubitemid 30064984)
22. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998;58:5071-4. (Pubitemid 28521163)
23. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 2001;95:92-5. (Pubitemid 32187079)
24. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000,96:1921-5. (Pubitemid 30661078)
25. Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000;19:617-23. (Pubitemid 30102912)
26. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 1999;341:452-3. (Pubitemid 29362524)
27. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001;285:324-8. (Pubitemid 32095036)
28. Schultz IJ, Kiemeney LA, Karthaus HF, Witjes JA, Willems JL, Swinkels DW et al. Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas. Clin Chem 2004;50:1425-8. (Pubitemid 38970655)
29. Shariat SF, Casella R, Khoddami SM, Hernandez G, Sulser T, Gasser TC et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 2004;171(2 pt 1):626-30. (Pubitemid 38090444)
30. Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007;8:128-36. (Pubitemid 46158371)